Evans syndrome (ES) is a rare autoimmune disorder defined by the combination of idiopathic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA), occasionally with immune neutropenia, in the absence of known underlying etiology.
1,2 ITP and AIHA may occur simultaneously or sequentially. The peak age of manifestation ranges between 5.5 and 7.7 years and both the sexes are equally affected. 1 ES has a chronic relapsing course with occasional remission; its clinical features reflect those of hemolytic anemia (pallor, lethargy, and jaundice) and thrombocytopenia (epistaxis, cutaneous or gingival bleeding, hematuria, menorrhagia, and fatigue). First-line therapy of ES is usually done with corticosteroids alone or in combination with intravenous immunoglobulin (IVIG), although the management of ES remains a challenge.
1,2
Patients with ITP have an increased risk of perioperative bleeding. 3, 4 Since the first report of a successful open cardiac surgery in ITP patients 3, 5 in the 1980s, no microsurgical free flap procedures have been described in ESpatients so far. In this report, we describe and discuss the first successful case of microvascular reconstruction of the mandible with free bone flaps in a patient with ES.
Case Report
A 12-year-old white woman was diagnosed ES in 2003. Initially, a cyclic corticosteroid therapy consisting of 10-day course of prednisone (25 mg, twice daily) was adopted depending on the platelets (PLT) count. The therapy failed to control recurrent episodes of gingival bleeding that occurred during the following years.
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Abstract
In this report, we describe the first successful case of microvascular free tissue transfer in a patient with Evans Syndrome (ES), a rare form of idiopathic thrombocytopenic purpura (ITP) and associated autoimmune hemolytic anemia (AIHA). Microvascular surgery in the setting of ES is likely to have higher complication rates because of the increased risk of postoperative bleeding and free flap thrombosis. The case presented here opens up to the feasibility of microvascular reconstruction of patients with coagulation disorders like ES. Every effort should be made to control for hemolytic, thrombocytopenic, and thrombophilic states associated with ES. In the absence of evidence-based treatment guidelines for ES, personalized treatment protocols with high-dose corticosteroids, immunoglobulin, and postoperative anticoagulation regimen are highly recommended.
In January 2007, at the age of 16 years, she was presented at our department with a fast-growing painless mass of the left mandibular body (►Fig. 1). This lesion caused teeth crowding, malocclusion, and facial deformity. Oral and dental care had been neglected for a long time owing to the risk of further hemorrhages. Computed tomographic scans showed a 14-cm-wide multiloculated bone lesion extending from the left mandibular angle to the contralateral premolar region, with cortical interruption (►Fig. 1). Blood tests revealed a severe thrombocytopenia (PLT 26 Â 10 9 /L) and a prolonged activated partial thromboplastin time (1.7 ratio) that was linked to the presence of antiphospholipid antibodies (aPL). AIHA disorder proved mild. A cushingoid state was present as a result of the chronic steroid therapy that was tapered and then interrupted. The patient was started on a 4-day course of dexamethasone (1-day upload course of 40 mg/four times daily, then 40 mg/four times daily), with a rapid increase of the PLT count (243 Â 10 9 /L), which remained stable above 100 Â 10 9 /L for several weeks. Within a normalized risk of bleeding, the patient underwent a biopsy of the bone lesion.
On the basis of the pathology report, a conclusive diagnosis of aggressive central giant cell granuloma (CGCG) was made, once hyperparathyroidism was ruled out. Furthermore, dental treatments were safely performed on an outpatient basis before the patient underwent subtotal mandibulectomy in June 2007. The 14-cm-long mandibular defect was immediately reconstructed with an osteomuscular fibular bone flap harvested from the right leg. The peroneal artery and accompanying veins were anastomosed to the right facial artery and vein and to the external jugular vein (►Fig. 2). No lifethreatening intraoperative bleeding occurred. At the end of the procedure, the PLT count was 138 Â 10 9 /L and hemoglobin was 8.90 g/L. Postoperative AIHA and ITP were controlled with the use of methylprednisolone intravenous dextran 40,000 PM at a dose of 20 mL/h and low-molecular-weight heparin (2,850 IU subcutaneous) were administered daily for 5 days. The patient's postoperative course was uneventful and the patient was discharged 18 days after surgery with a PLT count of 137 Â 10 9 /L.
The patient remained stable without major bleeding up to the age of 18 when she was asked for a full-arch dental rehabilitation (►Fig. 3). After consultation with the Hematology Department, a second vascularized fibula flap was planned to reconstruct the alveolar bone region and fill-up the vertical gap of the mandible. In November 2009, the patient underwent free fibula flap transfer from the left leg. Surgery was performed by the same operators (A.B., A.F., S.V., and G.B.), and the previously adopted operative and medical protocols were used. Postoperative course was uneventful and the patient was discharged 14 days after surgery with a PLT count of 146 Â10 9 /L. Two more surgeries were required for the completion of the dental rehabilitation protocol. The patient was free of disease at 3-year follow-up without any signs of AIHA and ITP (►Fig. 4).
Discussion
ES is a rare form (1%) of ITP and associated AIHA. 2 The increased risk of bleeding and life-threatening hemorrhages that is secondary to the accelerated PLT destruction caused by antiplatelet antibodies 1,6 usually contraindicate major surgery in ES patients. In the present case both diagnosis and treatment of the mandibular lesion have been postponed for more than 3 years since the initiation of the disease process, due to the fear of bleeding.
CGCG of the jaws is a reparative nonneoplastic, nonhyperparathyroidism-related process, whose treatment is usually conservative (i.e., curettage, corticosteroid injections, calcitonin, and interferon alfa). 7 Aggressive forms often require a radical approach, as in this case where facial disfigurement and malocclusion were present. 8 Fibula is the workhorse flap in pediatric mandibular reconstruction when long defects have to be spanned.
9
Bleeding disorders and thrombophilia are considered among the most relevant factors that can influence the outcome of microsurgical reconstruction.
10-12
A narrative review of the available literature turned out few case reports describing free flap failure in patients with undiagnosed hypercoagulation disorders, who underwent major head and neck reconstruction. [13] [14] [15] [16] [17] These authors state that hypercoagulation disorders may represent an independent factor affecting free flap success.
18
A recent internal survey from Wang et al 19 found an increased risk of free flap failure also in patients with known thrombophilic conditions; nonetheless, microsurgical reconstruction was not contraindicated in those patients when an accurate preoperative work-up and perioperative treatment of thrombophilia is performed, according to the American guidelines of College of Chest Physicians.
20
Thrombophilia increases the risk of thrombosis and free flap failure also in ES patients, especially when prolonged activated partial thromboplastin time is present, which is often related to aPLs, as in this case.
2,6
A variety of preoperative treatment strategies have been proposed in ES to boost PLT count before intervention and to minimize perioperative hemorrhages, including preoperative or concomitant splenectomy, corticosteroids medication, preoperative and/or postoperative IVIG, PLT transfusion, and immunosuppressive agent (danazol). 21, 22 First-line therapy for nonemergent indications is based on corticosteroids and/or IVIG. In emergent setting, blood and PLT transfusion may be administered to alleviate symptoms. Initial therapy for nonemergent indications is based on orally prednisone (1 mg/kg daily) for 3 or 4 weeks or prednisolone (1-4 mg/kg daily). Only 10 to 30% of ES patients on long-term corticosteroid therapy achieve stable remission and thrombocytopenia usually recurs in most cases after discontinuation.
1,2 When steroids are ineffective or toxic, the most common first-line therapy is concomitantly used of IVIG (0.4 g/kg/daily for 4 days).
1 Second-line therapy includes immunosuppressive agents (cyclosporine, mycophenolate mofetil, and danazol), the monoclonal antibody rituximab and chemotherapy (vincristine). Splenectomy is recommended in persistent ITP patient in case of a remission period less than 1 year after diagnosis, when the PLT count is consistently less than 20,000 Â 10 9 /L or when the patient is not responding to therapy 21 ; long-term remission in ES after splenectomy is less frequent than in uncomplicated ITP. Stem cell transplantation offers a further chance for severe and refractory cases.
1
Prolonged activated partial thromboplastin time in ITP patients is often related to aPL presence and give rise to a thrombotic risk (arterial and venous thrombosis, recurrent fetal loss).
2,6
As no successful experience is reported in ES patients who are candidates for major head and neck surgical resections and microsurgical reconstructions, we followed the recommendations of the British Haematology task force 23 and maintained PLT count above 100,000 Â 10 9 /L using perioperative high-dose corticosteroids.
2 Of importance, PLT counts should not exceed 200,000 Â 10 9 /L to minimize the associated thrombophilic risk. High-dose dexamethasone was effective to boost PLT count before intervention. Immunomodulating agents and IVIG were also prepared to be used in case of necessity, to diminish the substantial risk of thrombosis associated with aPLs in the postoperative. Nevertheless, thromboprophylaxis with daily subcutaneous injection of low-molecular-weight heparin was enough to prevent from vessel thrombosis and flap failure in the present case.
In conclusion, microvascular free flap surgery is feasible also in ES patients with autoimmune clotting disorders. ES patients who are candidates to microsurgical reconstructions should be carefully assessed for their hemolytic, thrombocytopenic, and thrombophilic states and treated accordingly to minimize the risk of free flap failure.
